NCT07466602 cfDNA Methylation for Liver Cancer Recurrence Detection
| NCT ID | NCT07466602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wuhan Ammunition Life-tech Co., Ltd |
| Condition | Primary Liver Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-09-02 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Primary liver cancer Exclusion Criteria: * Concurrent other malignant tumors; * Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy; * Negative methylation status prior to treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07466602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Liver Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07466602 currently recruiting?
Yes, NCT07466602 is actively recruiting participants. Contact the research team at litingting@amswh.com for enrollment information.
Where is the NCT07466602 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07466602 clinical trial?
NCT07466602 is sponsored by Wuhan Ammunition Life-tech Co., Ltd. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.